Non-Current Assets
Bristol-Myers Squibb·Balance Sheet Statement·10 metrics
Breakdown
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $94.6B | $93.7B | $92.6B | $92.4B | $94.7B | $96.9B | $90.0B | $86.5B |
| Goodwill | $21.7B | $21.8B | $21.7B | $21.7B | $21.8B | $21.7B | $21.8B | $21.7B |
| Other intangible assets—net | $29.4B | $27.0B | $23.3B | $22.5B | $21.4B | $20.5B | $19.1B | $18.2B |
| Property and equipment, net | $6.8B | $6.9B | $7.1B | $7.2B | $7.4B | $7.3B | $7.5B | $7.7B |
| Deferred Tax Assets and Other Non-Current Assets | $6.1B | $6.0B | $6.1B | $5.9B | $5.9B | $6.3B | $6.5B | $6.1B |
| Other non-current assets | $6.1B | $6.0B | $6.1B | $5.9B | $5.9B | $6.3B | $6.5B | $6.1B |
| Software and Technology Licenses, Net | $6.1B | $6.0B | $6.1B | $5.9B | $5.9B | $6.3B | $6.5B | $6.1B |
| Deferred tax assets | $3.3B | $3.6B | $4.2B | $4.0B | $4.6B | $5.0B | $5.4B | $5.2B |
| Long-term marketable securities | $357.0M | $324.0M | $320.0M | $344.0M | $346.0M | $406.0M | $396.0M | $366.0M |
| Deferred tax assets | $3.3B | $3.6B | $4.2B | $4.0B | $4.6B | $5.0B | -$392.0M | $161.0M |